Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Subcutaneous immunotherapy + aqueous extracts for Hymenoptera venom is a venom allergen immunotherapy product developed and marketed by **Anallergo**. The product consists of purified aqueous extracts of Hymenoptera venom, including bee, wasp, and hornet venoms, and is administered subcutaneously in the upper arm. It is indicated for the treatment of IgE-mediated Hymenoptera venom allergy, including bee, wasp, and hornet venom allergies. The mechanism of action involves the induction of immunological tolerance to venom allergens through a series of injections, shifting the patient's immune response from a hypersensitive Th2-biased state to a tolerant state mediated by Th1 and regulatory T cells. The product is approved and commercially available in Italy and other regions where Anallergo operates.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hymenoptera venom aqueous extract.